@article{wiloch_enomoto_smith_baynes_messenger_2024, title={Pharmacokinetics of intranasal and intramuscular flunixin in healthy grower pigs}, volume={1}, ISSN={["1365-2885"]}, url={https://doi.org/10.1111/jvp.13426}, DOI={10.1111/jvp.13426}, abstractNote={AbstractFlunixin meglumine is a nonsteroidal anti‐inflammatory drug approved to manage pyrexia associated with swine respiratory disease. In the United States, no analgesic drugs are approved for use in swine by the FDA, although they are needed to manage painful conditions. This study evaluated the pharmacokinetics and relative bioavailability of intranasal versus intramuscular flunixin in grower pigs. Six pigs received 2.2 mg/kg flunixin either intranasally via atomizer or intramuscularly before receiving flunixin via the opposite route following a 5‐day washout period. Plasma samples were collected over 60 h and analysed using ultra‐performance liquid chromatography and tandem mass spectrometry to detect flunixin plasma concentrations. A non‐compartmental pharmacokinetic analysis was performed. The median Cmax was 4.0 μg/mL and 2.7 μg/mL for intramuscular and intranasal administration, respectively, while the median AUCinf was 6.9 h μg/mL for intramuscular administration and 4.9 h μg/mL for intranasal administration. For both routes, the median Tmax was 0.2 h, and flunixin was detectable in some samples up to 60 h post‐administration. Intranasal delivery had a relative bioavailability of 88.5%. These results suggest that intranasal flunixin has similar, although variable, pharmacokinetic parameters to the intramuscular route, making it a viable route of administration for use in grower swine.}, journal={JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS}, author={Wiloch, Emily E. and Enomoto, Hiroko and Smith, Lilly and Baynes, Ronald E. and Messenger, Kristen M.}, year={2024}, month={Jan} }
 @article{meira_wiloch_nixon_yeatts_sheela_smith_baynes_2022, title={The pharmacokinetics of transdermal flunixin in lactating dairy goats}, volume={105}, ISSN={["1525-3198"]}, url={https://doi.org/10.3168/jds.2021-20460}, DOI={10.3168/jds.2021-20460}, abstractNote={Flunixin is a nonsteroidal anti-inflammatory drug approved for use in cattle to manage pyrexia associated with bovine respiratory disease, mastitis, and endotoxemia. In the United States, no nonsteroidal anti-inflammatory drugs are approved for use in goats, but analgesics are needed for management of painful conditions to improve animal welfare. The objective of this study was to evaluate the pharmacokinetics of transdermal flunixin in dairy goats to determine a milk withdrawal interval (WDI) to avoid violative residue contamination in the food supply. Six adult lactating dairy goats received 3.3 mg/kg of transdermal flunixin before milk, interstitial fluid (ISF), and blood samples were collected at various time points for 360 h. The samples were analyzed using tandem mass spectrometry to detect flunixin as well as the flunixin marker metabolite, 5-hydroxyflunixin followed by a pharmacokinetic WDI calculation using the US Food and Drug Administration tolerance limit method to propose safe residue levels in goat milk. The mean flunixin apparent plasma half-life was 21.63 h. The apparent milk half-life for 5-hydroxyflunixin was 17.52 h. Our findings provide a milk WDI of 60 h using the US Food and Drug Administration tolerance of 0.002 µg/mL (established for bovine milk) and a more conservative WDI of 96 h using a limit of quantification of 0.001 µg/mL following the extralabel use of transdermal flunixin in dairy goats.}, number={1}, journal={JOURNAL OF DAIRY SCIENCE}, publisher={American Dairy Science Association}, author={Meira, Enoch B. de S., Jr Jr and Wiloch, Emily E. and Nixon, Emma and Yeatts, James L. and Sheela, Farha Ferdous and Smith, Geof W. and Baynes, Ronald E.}, year={2022}, month={Jan}, pages={549–559} }